-
-
-
-
-
-
-
MBX (MBX) Reports Q4 Loss of $0.49
-
-
-
-
-
-
-
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
-
-
-
-
-
-
-
Microbix Partners with SEKISUI Diagnostics to Support COVID/Flu Tests
-
-
-
-
-
-
-
Microbix Client Labquality Introduces Novel EQA Scheme at ESCV
-
-
-
-
-
-
-
Microbix & Bulgaria’s NCIPD Execute Supply Agreement
-
-
-
-
-
-
-
Microbix’s Clot-Buster Drug Project Advances
-
-
-
-
-
-
-
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
-
1,205,330 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

